Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01398046 · ClinicalTrials.gov registry record · Phase 1
Effects of Gastric pH on the Pharmacokinetics of Dasatinib
A Phase 1 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT01398046 is a Phase 1 study that has completed, run by University of California, San Francisco. The registered enrollment target is 10 participants.
The verdict
NCT01398046, a Phase 1 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The goal of this study is to evaluate the ability of a natural supplement (betaine hydrochloride) to affect the absorption of dasatinib in healthy volunteers. The investigators predict that betaine hydrochloride will increase the absorption of dasatinib, in volunteers pre-treated with proton-pump inhibitors (PPIs).
Interventions
- DRUG Dasatinib
- DRUG Dasatinib plus Rabeprazole
- DRUG Dasatinib plus Rabeprazole AND Betaine Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2011-08 |
| Est. Completion | 2014-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01398046
The ClinicalTrials.gov registry entry for NCT01398046 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Dasatinib is the first listed.
NCT01398046 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01398046 about?
NCT01398046 is a clinical study titled "Effects of Gastric pH on the Pharmacokinetics of Dasatinib". The goal of this study is to evaluate the ability of a natural supplement (betaine hydrochloride) to affect the absorption of dasatinib in healthy volunteers. The investigators predict that betaine hydrochloride will increase the absorption of dasatinib, in volunteers pre-treated with proton-pump in...
What is the current status of trial NCT01398046?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2011-08. Estimated completion is 2014-02.
What interventions are being tested in trial NCT01398046?
The interventions under investigation include: Dasatinib (DRUG), Dasatinib plus Rabeprazole (DRUG), Dasatinib plus Rabeprazole AND Betaine Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT01398046?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.